ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2026
Published Date: 2026-03-11
|
Report Code: QYRE-Auto-22V17810
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024
BUY CHAPTERS

Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2026

Code: QYRE-Auto-22V17810
Report
2026-03-11
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
TEVA
Huadong Medicine
Sino Biopharm

Liraglutide for The Treatment of Diabetes and Obesity Market

The global Liraglutide for The Treatment of Diabetes and Obesity market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Liraglutide for The Treatment of Diabetes and Obesity competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Liraglutide is a medication approved for the treatment of both type 2 diabetes mellitus and obesity.It belongs to the class of glucagon-like peptide-1(GLP-1)receptor agonists,which can enhance glucose-dependent insulin secretion,suppress glucagon release,slow gastric emptying,and promote satiety,thereby improving glycemic control and potentially aiding in weight loss.
The North American market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Liraglutide for The Treatment of Diabetes and Obesity is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Liraglutide for The Treatment of Diabetes and Obesity include Novo Nordisk, Teva, Huadong Medicine, Sino Biopharm, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Liraglutide for The Treatment of Diabetes and Obesity market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Liraglutide for The Treatment of Diabetes and Obesity. The Liraglutide for The Treatment of Diabetes and Obesity market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Liraglutide for The Treatment of Diabetes and Obesity market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Liraglutide for The Treatment of Diabetes and Obesity manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Liraglutide for The Treatment of Diabetes and Obesity Market Report

Report Metric Details
Report Name Liraglutide for The Treatment of Diabetes and Obesity Market
Segment by Type
  • Original Drug
  • Generic Drug
by Application
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, Teva, Huadong Medicine, Sino Biopharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Liraglutide for The Treatment of Diabetes and Obesity manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Liraglutide for The Treatment of Diabetes and Obesity sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Liraglutide for The Treatment of Diabetes and Obesity Market report?

Ans: The main players in the Liraglutide for The Treatment of Diabetes and Obesity Market are Novo Nordisk, Teva, Huadong Medicine, Sino Biopharm

What are the Application segmentation covered in the Liraglutide for The Treatment of Diabetes and Obesity Market report?

Ans: The Applications covered in the Liraglutide for The Treatment of Diabetes and Obesity Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Liraglutide for The Treatment of Diabetes and Obesity Market report?

Ans: The Types covered in the Liraglutide for The Treatment of Diabetes and Obesity Market report are Original Drug, Generic Drug

1 Liraglutide for The Treatment of Diabetes and Obesity Market Overview
1.1 Product Definition
1.2 Liraglutide for The Treatment of Diabetes and Obesity by Type
1.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Value by Type: 2025 vs 2032
1.2.2 Original Drug
1.2.3 Generic Drug
1.3 Liraglutide for The Treatment of Diabetes and Obesity by Application
1.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Estimates and Forecasts
1.4.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue 2021–2032
1.4.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales 2021–2032
1.4.3 Global Liraglutide for The Treatment of Diabetes and Obesity Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Liraglutide for The Treatment of Diabetes and Obesity Market Competition by Manufacturers
2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Manufacturers (2021–2026)
2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Liraglutide for The Treatment of Diabetes and Obesity, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Product Types and Applications
2.7 Global Key Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Date of Entry into the Industry
2.8 Global Liraglutide for The Treatment of Diabetes and Obesity Market Competitive Situation and Trends
2.8.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Liraglutide for The Treatment of Diabetes and Obesity Players Market Share by Revenue
2.8.3 Global Liraglutide for The Treatment of Diabetes and Obesity Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Liraglutide for The Treatment of Diabetes and Obesity Market Scenario by Region
3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021–2032
3.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2021–2026
3.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region: 2027–2032
3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region: 2021–2032
3.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region: 2021–2026
3.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region: 2027–2032
3.4 North America Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
3.4.1 North America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021–2032)
3.4.3 North America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
3.5.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021–2032)
3.5.3 Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Region
3.6.1 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2021–2032)
3.6.3 Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
3.7.1 Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021–2032)
3.7.3 Latin America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Facts & Figures by Country
3.8.1 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021–2032)
3.8.3 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021–2032)
4.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021–2026)
4.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2027–2032)
4.1.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2021–2032)
4.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Type (2021–2032)
4.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Type (2021–2026)
4.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Type (2027–2032)
4.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Type (2021–2032)
4.3 Global Liraglutide for The Treatment of Diabetes and Obesity Price by Type (2021–2032)
5 Segment by Application
5.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021–2032)
5.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021–2026)
5.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2027–2032)
5.1.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Application (2021–2032)
5.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Application (2021–2032)
5.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Application (2021–2026)
5.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Application (2027–2032)
5.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Application (2021–2032)
5.3 Global Liraglutide for The Treatment of Diabetes and Obesity Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Huadong Medicine
6.3.1 Huadong Medicine Company Information
6.3.2 Huadong Medicine Description and Business Overview
6.3.3 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
6.3.5 Huadong Medicine Recent Developments/Updates
6.4 Sino Biopharm
6.4.1 Sino Biopharm Company Information
6.4.2 Sino Biopharm Description and Business Overview
6.4.3 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
6.4.5 Sino Biopharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Liraglutide for The Treatment of Diabetes and Obesity Industry Chain Analysis
7.2 Liraglutide for The Treatment of Diabetes and Obesity Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Liraglutide for The Treatment of Diabetes and Obesity Production Mode & Process Analysis
7.4 Liraglutide for The Treatment of Diabetes and Obesity Sales and Marketing
7.4.1 Liraglutide for The Treatment of Diabetes and Obesity Sales Channels
7.4.2 Liraglutide for The Treatment of Diabetes and Obesity Distributors
7.5 Liraglutide for The Treatment of Diabetes and Obesity Customer Analysis
8 Liraglutide for The Treatment of Diabetes and Obesity Market Dynamics
8.1 Liraglutide for The Treatment of Diabetes and Obesity Industry Trends
8.2 Liraglutide for The Treatment of Diabetes and Obesity Market Drivers
8.3 Liraglutide for The Treatment of Diabetes and Obesity Market Challenges
8.4 Liraglutide for The Treatment of Diabetes and Obesity Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novo Nordisk
TEVA
Huadong Medicine
Sino Biopharm
List of Tables
 Table 1. Global Liraglutide for The Treatment of Diabetes and Obesity Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Liraglutide for The Treatment of Diabetes and Obesity Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Liraglutide for The Treatment of Diabetes and Obesity Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose) of Key Manufacturers (2021–2026)
 Table 5. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Liraglutide for The Treatment of Diabetes and Obesity Average Price (US$/Dose) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Liraglutide for The Treatment of Diabetes and Obesity, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Product Types and Applications
 Table 12. Global Key Manufacturers of Liraglutide for The Treatment of Diabetes and Obesity, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Liraglutide for The Treatment of Diabetes and Obesity Companies by Tier (Tier 1, Tier 2, Tier 3), based on Liraglutide for The Treatment of Diabetes and Obesity Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (K Dose), 2021–2026
 Table 18. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Region (2021–2026)
 Table 19. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (K Dose), 2027–2032
 Table 20. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Region (2027–2032)
 Table 21. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Region (2021–2026)
 Table 23. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Region (2027–2032)
 Table 25. North America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2021–2026
 Table 27. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2027–2032
 Table 28. North America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2021–2026
 Table 32. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2027–2032
 Table 33. Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (K Dose), 2021–2026
 Table 37. Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (K Dose), 2027–2032
 Table 38. Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2021–2026
 Table 42. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2027–2032
 Table 43. Latin America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2021–2026
 Table 47. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (K Dose), 2027–2032
 Table 48. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose) by Type (2021–2026)
 Table 51. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose) by Type (2027–2032)
 Table 52. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2021–2026)
 Table 53. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2027–2032)
 Table 54. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Type (2021–2026)
 Table 57. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Type (2027–2032)
 Table 58. Global Liraglutide for The Treatment of Diabetes and Obesity Price (US$/Dose) by Type (2021–2026)
 Table 59. Global Liraglutide for The Treatment of Diabetes and Obesity Price (US$/Dose) by Type (2027–2032)
 Table 60. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose) by Application (2021–2026)
 Table 61. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose) by Application (2027–2032)
 Table 62. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Application (2021–2026)
 Table 63. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Application (2027–2032)
 Table 64. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Application (2021–2026)
 Table 67. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Application (2027–2032)
 Table 68. Global Liraglutide for The Treatment of Diabetes and Obesity Price (US$/Dose) by Application (2021–2026)
 Table 69. Global Liraglutide for The Treatment of Diabetes and Obesity Price (US$/Dose) by Application (2027–2032)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 73. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. Teva Company Information
 Table 76. Teva Description and Business Overview
 Table 77. Teva Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 78. Teva Liraglutide for The Treatment of Diabetes and Obesity Product
 Table 79. Teva Recent Developments/Updates
 Table 80. Huadong Medicine Company Information
 Table 81. Huadong Medicine Description and Business Overview
 Table 82. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 83. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product
 Table 84. Huadong Medicine Recent Developments/Updates
 Table 85. Sino Biopharm Company Information
 Table 86. Sino Biopharm Description and Business Overview
 Table 87. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 88. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product
 Table 89. Sino Biopharm Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Liraglutide for The Treatment of Diabetes and Obesity Distributors List
 Table 93. Liraglutide for The Treatment of Diabetes and Obesity Customers List
 Table 94. Liraglutide for The Treatment of Diabetes and Obesity Market Trends
 Table 95. Liraglutide for The Treatment of Diabetes and Obesity Market Drivers
 Table 96. Liraglutide for The Treatment of Diabetes and Obesity Market Challenges
 Table 97. Liraglutide for The Treatment of Diabetes and Obesity Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Liraglutide for The Treatment of Diabetes and Obesity
 Figure 2. Global Liraglutide for The Treatment of Diabetes and Obesity Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Liraglutide for The Treatment of Diabetes and Obesity Market Share by Type: 2025 & 2032
 Figure 4. Original Drug Product Picture
 Figure 5. Generic Drug Product Picture
 Figure 6. Global Liraglutide for The Treatment of Diabetes and Obesity Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Liraglutide for The Treatment of Diabetes and Obesity Market Share by Application: 2025 & 2032
 Figure 8. Hospital and Clinic
 Figure 9. Retail Pharmacies
 Figure 10. Other
 Figure 11. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size (US$ Million), 2021–2032
 Figure 13. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), 2021–2032
 Figure 14. Global Liraglutide for The Treatment of Diabetes and Obesity Average Price (US$/Dose), 2021–2032
 Figure 15. Liraglutide for The Treatment of Diabetes and Obesity Report Years Considered
 Figure 16. Liraglutide for The Treatment of Diabetes and Obesity Sales Share by Manufacturers in 2025
 Figure 17. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Liraglutide for The Treatment of Diabetes and Obesity Players: Market Share by Revenue in Liraglutide for The Treatment of Diabetes and Obesity in 2025
 Figure 19. Liraglutide for The Treatment of Diabetes and Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021–2032)
 Figure 22. North America Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Country (2021–2032)
 Figure 23. United States Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021–2032)
 Figure 26. Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Region (2021–2032)
 Figure 34. China Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021–2032)
 Figure 42. Latin America Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of Liraglutide for The Treatment of Diabetes and Obesity by Type (2021–2032)
 Figure 53. Global Revenue Market Share of Liraglutide for The Treatment of Diabetes and Obesity by Type (2021–2032)
 Figure 54. Global Liraglutide for The Treatment of Diabetes and Obesity Price (US$/Dose) by Type (2021–2032)
 Figure 55. Global Sales Market Share of Liraglutide for The Treatment of Diabetes and Obesity by Application (2021–2032)
 Figure 56. Global Revenue Market Share of Liraglutide for The Treatment of Diabetes and Obesity by Application (2021–2032)
 Figure 57. Global Liraglutide for The Treatment of Diabetes and Obesity Price (US$/Dose) by Application (2021–2032)
 Figure 58. Liraglutide for The Treatment of Diabetes and Obesity Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024
Global GLP 1 Agonists for Obesity Market Research Report 2024
Liraglutide Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1RA based Therapy for Obesity Market Research Report 2024
Global GLP 1 Weight Loss Pill Market Research Report 2024
Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025
Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025
Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025
Global GLP 1 Receptor Agonist Drugs Market Research Report 2024
Global GLP 1 Weight Loss Drug Market Research Report 2024
Global Oral GLP 1 Agonist Market Research Report 2024
Global GLP 1 Agonist Injection Market Research Report 2024
GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Weight Loss Injection Market Research Report 2024
Global Dulaglutide Market Research Report 2024
Global GLP 1 Receptor Antagonist Market Research Report 2024
Global GLP 1 Drug Peptide API Market Research Report 2024
GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1RA Therapy Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions